Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics, preoperative systemic inflammatory response markers, and postoperative metastatic pattern of patients with stage III colon cancer

From: Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer

Variable Overall [cases (%)] High PNI group [cases (%)] Low PNI group [cases (%)] P value
Total 274 152 (55.5) 122 (44.5)  
Age (years)
 ≤ 60 189 (69.0) 112 (73.7) 77 (63.1) 0.061
 > 60 85 (31.0) 40 (26.3) 45 (36.9)  
Sex 0.274
 Male 156 (56.9) 91 (59.9) 65 (46.7)  
 Female 118 (43.1) 61 (40.1) 57 (53.3)  
Baseline BMI (kg/m2) 0.154
 < 18.5 28 (10.2) 11 (7.2) 17 (13.9)  
 18.5–25.0 187 (68.2) 105 (69.1) 82 (67.2)  
 > 25.0 59 (21.5) 36 (23.7) 23 (18.9)  
Hemoglobin (g/L) < 0.001
 < 90 42 (15.3) 11 (7.2) 31 (25.4)  
 ≥ 90 232 (84.7) 141 (92.8) 91 (74.6)  
Tumor location < 0.001
 Right-sided colon 103 (37.6) 44 (28.9) 59 (48.4)  
 Left-sided colon 171 (62.4) 108 (71.1) 63 (51.6)  
Tumor size (cm) < 0.001
 ≤ 4 140 (51.1) 91 (59.9) 49 (40.2)  
 > 4 134 (48.9) 61 (40.1) 73 (59.8)  
Differentiation 0.962
 Well/moderate 207 (75.5) 115 (75.7) 92 (75.4)  
 Poor/undifferentiated 67 (24.5) 37 (24.3) 30 (24.6)  
T stage 0.754
 T1–T2 12 (4.4) 6 (3.9) 6 (4.9)  
 T3 121 (44.2) 70 (46.1) 51 (41.8)  
 T4 141 (51.5) 76 (50.0) 65 (53.3)  
N stage 0.762
 N1 189 (69.0) 106 (69.7) 83 (68.0)  
 N2 85 (31.0) 46 (30.3) 39 (32.0)  
TNM stage 0.290
 IIIA 10 (3.6) 6 (3.9) 4 (3.3)  
 IIIB 202 (73.7) 117 (77) 85 (69.7)  
 IIIC 62 (22.6) 29 (19.1) 33 (27.0)  
Preoperative serum CEA level (ng/mL) 0.031
 ≤ 5 159 (58.0) 97 (63.8) 62 (50.8)  
 > 5 115 (42.0) 55 (36.2) 60 (49.2)  
Cycles of XELOX adjuvant chemotherapya 0.296
 < 6 53 (19.3) 26 (17.1) 27 (22.1)  
 6–8 221 (80.7) 126 (82.9) 95 (77.9)  
LMR  
 ≤ 4.00 144 (52.6) 59 (38.8) 85 (69.7) < 0.001
 > 4.00 130 (47.4) 93 (61.2) 37 (30.3)  
NLR  
 ≤ 2.05 134 (48.9) 90 (59.2) 44 (36.1) < 0.001
 > 2.05 140 (51.1) 62 (40.8) 78 (63.9)  
PLR  
 ≤ 142.99 134 (48.9) 102 (67.1) 32 (26.2) < 0.001
 > 142.99 140 (51.1) 50 (32.9) 90 (73.8)  
Postoperative metastasisb 53 (19.3) 22 (14.5) 31 (25.4) 0.024
Liver metastasis 21 (7.7) 9 (5.9) 12 (9.8) 0.231
Lung metastasis 12 (4.4) 5 (3.3) 7 (5.7) 0.331
Abdominopelvic metastasis 16 (5.9) 5 (3.3) 11 (9.0) 0.053
  1. PNI prognostic nutritional index, BMI body mass index, TNM stage clinical tumor-node-metastasis stage, CEA carcinoembryonic antigen, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
  2. aXELOX adjuvant chemotherapy was administrated as follow: oxaliplatin 130 mg/m2 administered intravenously on day 1 and capecitabine 1000 mg/m2 administered orally twice daily on days 1–14 for a 3-week cycle
  3. bThe metastatic sites of 4 patients were not recorded